Psychedelic Therapy Scrutinized by FDA Advisory Committee?

Mason Marks

DOI: https://doi.org/10.1001/jama.2024.13370

IF: 11.816

2024-07-30

JAMA

Abstract:This Viewpoint analyzes the Psychopharmacologic Drugs Advisory Committee’s decisions regarding 3,4-methylenedioxymethamphetamine–assisted therapy and what they mean for psychedelic research.

medicine, general & internal

What problem does this paper attempt to address?

Psychedelic research at a crossroads

Stacey B. Armstrong,Alan K. Davis

DOI: https://doi.org/10.1126/science.adt1024

IF: 56.9

2024-09-21

Science

Abstract:There is an urgent need to develop better treatments for mental health conditions that affect one in every eight people in the world. To combat this concern, psychedelic drugs have been combined with psychotherapy and studied in clinical trials in the United States and Europe. Psychedelics are hallucinogenic drugs that alter brain activity and facilitate altered states of consciousness. The proposed benefits of psychedelic-assisted therapy (PAT) include relatively short treatment times and stronger effects compared to other treatments. Although results of trials using MDMA for trauma or psilocybin for depression are promising, PAT is controversial because many questions about its safety and effectiveness are unanswered. This is evident in the recent ruling by the US Food and Drug Administration against the approval of MDMA therapy for post-traumatic stress disorder and the retraction of several papers about MDMA trials owing to unethical conduct by study therapists and data integrity, among other concerns. This field is at a crossroads, and the research community must address several obstacles to transition from exploratory trials to established, evidence-based treatments while avoiding pitfalls that can hinder advancement.

multidisciplinary sciences
Decision-Making around Psychedelics for Depression and Anxiety: a Model Based on Online Discussions

David T. Kryszajtys,Jacqueline L. Bender,Brian Rush,Carol J. Strike

DOI: https://doi.org/10.1007/s11469-023-01148-1

IF: 8

2023-09-27

International Journal of Mental Health and Addiction

Abstract:Little is known about how people decide to use psychedelics to self-treat depression and anxiety, though the practice is growing. We explored online community discussions of members' decisions around self-treatment with psychedelics for depression or anxiety. We used constructivist grounded theory to select and analyze 98 members' posts across 95 discussion threads (99, 552 words) and identified a four-stage decision-making model. In stage one, decision-making began after dissatisfaction with standard mental health treatment. In stage two, members considered various psychedelic self-treatment options but explained that information was limited. In stage three, they engaged in trial and error when making decisions, despite uncertainties around safety. In stage four, they continued or discontinued self-treatment. Those who continued adapted their practice to their evolving treatment needs. Firsthand and peers' experiences informed decisions. Available scientific evidence initially validated the psychedelic self-treatment but were not instructive. Many avoided healthcare and official information sources due to stigma and legal concerns. Research and knowledge translation efforts are needed to identify general concerns with self-treatment and provide user-informed decisional support to reduce harm and maximize benefit. Services supporting psychedelic self-treatment decisions can leverage our findings to create resources based on people's lived experiences.

psychiatry,substance abuse,psychology, clinical
Psychedelics field looks ahead after FDA advisers' rejection

Kai Kupferschmidt

DOI: https://doi.org/10.1126/science.adr0286

IF: 56.9

2024-06-15

Science

Abstract:Reeling from negative vote on MDMA-assisted PTSD therapy, researchers seek lessons for future studies

multidisciplinary sciences
Psychedelic Therapy: A Primer for Primary Care Clinicians—3,4-Methylenedioxy-methamphetamine (MDMA)

Kenneth Shinozuka,Burton J. Tabaac,Alejandro Arenas,Bryce D. Beutler,Kirsten Cherian,Viviana D. Evans,Chelsey Fasano,Owen S. Muir

DOI: https://doi.org/10.1097/mjt.0000000000001722

2024-03-23

American Journal of Therapeutics

Abstract:Background: After becoming notorious for its use as a party drug in the 1980s, 3,4-methylenedioxy-methampetamine (MDMA), also known by its street names "molly" and "ecstasy," has emerged as a powerful treatment for post-traumatic stress disorder (PTSD). Areas of Uncertainty: There are extensive data about the risk profile of MDMA. However, the literature is significantly biased. Animal models demonstrating neurotoxic or adverse effects used doses well beyond the range that would be expected in humans (up to 40 mg/kg in rats compared with roughly 1–2 mg/kg in humans). Furthermore, human samples often comprise recreational users who took other substances in addition to MDMA, in uncontrolled settings. Therapeutic Advances: Phase III clinical trials led by the Multidisciplinary Association for Psychedelic Studies (MAPS) have shown that MDMA-assisted psychotherapy has an effect size of d = 0.7–0.91, up to 2–3 times higher than the effect sizes of existing antidepressant treatments. 67%–71% of patients who undergo MDMA-assisted psychotherapy no longer meet the diagnostic criteria for PTSD within 18 weeks. We also describe other promising applications of MDMA-assisted psychotherapy for treating alcohol use disorder, social anxiety, and other psychiatric conditions. Limitations: Thus far, almost all clinical trials on MDMA have been sponsored by a single organization, MAPS. More work is needed to determine whether MDMA-assisted therapy is more effective than existing nonpharmacological treatments such as cognitive behavioral therapy. Conclusions: Phase III trials suggest that MDMA is superior to antidepressant medications for treating PTSD. Now that MAPS has officially requested the Food and Drug Administration to approve MDMA as a treatment for PTSD, legal MDMA-assisted therapy may become available as soon as 2024.

pharmacology & pharmacy
Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines

Sean J Belouin,Lynnette A Averill,Jack E Henningfield,Stephen N Xenakis,Ingrid Donato,Charles S Grob,Ann Berger,Veronica Magar,Alicia L Danforth,Brian T Anderson

DOI: https://doi.org/10.1016/j.neuropharm.2022.109214

IF: 5.273

2022-11-15

Neuropharmacology

Abstract:There is mounting evidence suggesting psychedelic and entactogen medicines (namely psilocybin and 3,4-methylenedioxymethamphetamine [MDMA]), in conjunction with proper psychosocial support, hold the potential to provide safe, rapid acting, and robust clinical improvements with durable effects. In the US, both psilocybin and MDMA have been granted Breakthrough Therapy designations by the US Food and Drug Administration and may potentially receive full FDA approval with similar regulatory considerations occurring in multiple countries. At the same time, regulatory changes are poised to increase access to legal or decriminalized psychedelic use in various non-medical settings. This review provides a brief discussion on the historical use of psychedelic medicines, the status of the empirical evidence, and numerous significant policy considerations that must be thoughtfully addressed regarding standards-of-practice, consumer protection, engagement of communities, safeguarding access for all, and developing data standards, which supports the responsible, accountable, safe, and ethical uses of these medicines in clinical, faith-based, and other contexts. We provide suggestions for how public health and harm reduction can be supported through a public-private partnership that engages a community of stakeholders from various disciplines in the co-creation and dissemination of best practices and public policies.
A regulatory framework review of Schedule I psychedelics in the United States

Kevin Herkenham

DOI: https://doi.org/10.1002/jac5.1841

2023-06-26

Abstract:Psychoactive substances such as psilocybin and 3,4‐methylenedioxy‐methamphetamine (MDMA) are currently being investigated for a variety of psychiatric indications including major depressive disorder and post‐traumatic stress disorder. It is critical that clinicians working in the mental health field understand the regulatory framework that balances access and control for such substances. While both psilocybin and MDMA are designated as “Breakthrough Therapy” by the Food and Drug Administration (FDA), they remain classified as Schedule I substances under the Controlled Substances Act (CSA) of 1970. There are programs such as Expanded Access (EA) and federal Right‐to‐Try (RTT) legislation that can accommodate patient access to investigational drugs under certain circumstances, but these programs are not without their limits—particularly for Schedule I substances that do not currently have an accepted medical use per the CSA. It is in the clinical community's best interest to understand the administrative procedures, key court cases, and federal legislative initiatives related to these substances in order to make well‐informed decisions for themselves and their patients. Furthermore, understanding the administrative proceedings related to controlled substances will also allow subject matter experts to participate in and shape the policies governing such substances.

English Else
The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns

Brian A. Baldo

DOI: https://doi.org/10.1007/s00204-024-03765-8

2024-05-16

Archives of Toxicology

Abstract:The phenylethylamine, 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'), is the prototypical example of an entactogen. Its original placement in highly restrictive drug usage categories in the US and UK, led to an inevitable restriction on MDMA neuroscience research and treatment. The dominant pharmacological effects of MDMA are its properties of release and inhibition of reuptake of amine neurotransmitter transporters for dopamine, norepinephrine, and serotonin. MDMA is an agonist of a wide range of receptors; its mood-altering effects are mediated via 5-HT 2A receptors; this receptor may also mediate its effects on body temperature, analgesia, and anxiolytic properties. The mechanisms underlying MDMA's entactogenic properties of sociability and interpersonal closeness are not known but release and involvement of oxytocin, a peptide thought by some to be involved in social bonding, has been suggested. Adverse effects of MDMA are mostly transient; acute multiorgan adverse effects occurring during raves or crowded dance gatherings include dehydration, hyperthermia, seizures, rhabdomyolysis, disseminated intravascular coagulation, and acute renal failure. Deaths following MDMA taken by itself are rare compared to fatalities following coadministration with other drugs. A recent FDA-approved phase 3 clinical trial of MDMA for post-traumatic stress disorder (PTSD) led to the conclusion that MDMA-assisted therapy represents a potential breakthrough treatment meriting expedited clinical evaluation. Despite the ongoing deliberations by the FDA and EMA for approval of MDMA treatment of PTSD, the Australian Therapeutic Goods Administration (TGA) recently announced that after an evaluation of the therapeutic value, benefits, and risks of MDMA, it will permit its prescribing for the treatment of PTSD. Further examples of regulatory relaxation toward MDMA-assisted psychotherapy are underway. These include the FDA's recently approved clinical trial to assess MDMA's efficacy in the treatment of "asociality" in patients with schizophrenia and an open trial of MDMA treatment for alcohol-use disorder which showed decreased alcohol consumption. There are also ongoing studies on the little understood startle response, anxiety associated with life-threatening illness, and social anxiety in autistic adults.

toxicology
Psychedelic Therapy: A Primer for Primary Care Clinicians—The Strengths, Weaknesses, Opportunities, and Threats of Psychedelic Therapeutics

Owen S. Muir,Kenneth Shinozuka,Bryce D. Beutler,Alejandro Arenas,Kirsten Cherian,Viviana D. Evans,Chelsey Fasano,Burton J. Tabaac

DOI: https://doi.org/10.1097/mjt.0000000000001720

2024-03-23

American Journal of Therapeutics

Abstract:The reviews in this special edition have presented a primer on the state of the literature for 7 different psychedelic compounds and their plausible roles in medicine. In a common format underscoring strengths, weakness, opportunities, and threats (SWOT), this article addresses how psychedelic compounds fit into the broader health care landscape for indicated conditions. Historically, psychiatric pathologies have been treated with small-molecule compounds that have limited effect sizes and carry a variety of adverse effect profiles. Psychedelic medicines offer the opportunity to provide more potent and rapidly acting treatments. It is crucial to note that this is an emerging field of medicine, and only one of these compounds (esketamine) is currently Food and Drug Administration-approved for depression. The other compounds discussed are investigational, and this discussion is both imaginative and prospective in nature.

pharmacology & pharmacy
Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money

Keith Humphreys,P Todd Korthuis,Daniel Stjepanović,Wayne Hall

DOI: https://doi.org/10.1146/annurev-psych-020124-023532

2024-08-02

Abstract:Therapeutic claims about many psychedelic drugs have not been evaluated in any studies of even modest rigor. The science of psychedelic drugs is strengthening however, making it easier to differentiate some promising findings amid the hype that suffuses this research area. Ketamine has risks of adverse side effects (e.g., addiction and cystitis), but multiple studies suggest it can benefit individuals with treatment-resistant depression. Other therapeutic signals from psychedelic drug research that merit rigorous replication studies include 3,4-Methylenedioxymethamphetamine (MDMA) for post-traumatic stress disorder (PTSD) and psilocybin for depression, end of life dysphoria, and alcohol use disorder. The precise mechanisms through which psychedelic drugs can produce benefit and harm are not fully understood. Rigorous research is the best path forward for evaluating the therapeutic potential and mechanisms of psychedelic drugs. Policies governing the clinical use of these drugs should be informed by evidence and prioritize the protection of public health over the profit motive.
Developing an Ethics and Policy Framework for Psychedelic Clinical Care

Amy L. McGuire,I. Glenn Cohen,Dominic Sisti,Matthew Baggott,Yuria Celidwen,Neşe Devenot,Sabrina Gracias,Charles Grob,Ifetayo Harvey,Brent Kious,Mason Marks,Michael Mithoefer,Elizabeth Nielson,Dost Öngür,Alexandra Pallas,Andrew Peterson,Eduardo E. Schenberg,Paul Summergrad,Brett Waters,Monnica T. Williams,David B. Yaden

DOI: https://doi.org/10.1001/jamanetworkopen.2024.14650

2024-06-06

JAMA Network Open

Abstract:Importance As government agencies around the globe contemplate approval of the first psychedelic medicines, many questions remain about their ethical integration into mainstream medical practice. Objective To identify key ethics and policy issues related to the eventual integration of psychedelic therapies into clinical practice. Evidence Review From June 9 to 12, 2023, 27 individuals representing the perspectives of clinicians, researchers, Indigenous groups, industry, philanthropy, veterans, retreat facilitators, training programs, and bioethicists convened at the Banbury Center at Cold Spring Harbor Laboratory. Prior to the meeting, attendees submitted key ethics and policy issues for psychedelic medicine. Responses were categorized into 6 broad topics: research ethics issues; managing expectations and informed consent; therapeutic ethics; training, education, and licensure of practitioners; equity and access; and appropriate role of gatekeeping. Attendees with relevant expertise presented on each topic, followed by group discussion. Meeting organizers (A.L.M., I.G.C., D.S.) drafted a summary of the discussion and recommendations, noting points of consensus and disagreement, which were discussed and revised as a group. Findings This consensus statement reports 20 points of consensus across 5 ethical issues (reparations and reciprocity, equity, and respect; informed consent; professional boundaries and physical touch; personal experience; and gatekeeping), with corresponding relevant actors who will be responsible for implementation. Areas for further research and deliberation are also identified. Conclusions and Relevance This consensus statement focuses on the future of government-approved medical use of psychedelic medicines in the US and abroad. This is an incredibly exciting and hopeful moment, but it is critical that policymakers take seriously the challenges ahead.

medicine, general & internal
Psychedelics in Addiction Treatment—Navigating a Sociopolitical Rift

Nicky J. Mehtani,Brian T. Anderson,Jennifer M. Mitchell

DOI: https://doi.org/10.1001/jamaneurol.2023.5173

IF: 29.907

2024-01-16

JAMA Neurology

Abstract:This Viewpoint discusses the use of psychedelics in treatment for substance use disorders.

clinical neurology
Exploring the regulatory framework of psychedelics in the US & Europe

Hitesh Kumar Behera,Ramesh Joga,Sravani Yerram,Praveena Karnati,Tejaswini Mergu,Kajal Gandhi,Sowndharya M,Deepak Nathiya,Ravindra Pal Singh,Saurabh Srivastava,Sandeep Kumar

DOI: https://doi.org/10.1016/j.ajp.2024.104242

2024-09-17

Abstract:Psychedelic drug therapy has gained prominence for its potential in treating various mental health conditions, including depression, post-traumatic stress disorder (PTSD), and anxiety. Psychedelic treatment differs from conventional psychiatric approaches in mode of action, legal status, and treatment approach. This work delves into the therapeutic potential, mechanisms, and regulatory approvals of key psychedelic substances like psilocybin, 3,4-Methyl enedioxy methamphetamine (MDMA), mescaline, ketamine, and Lysergic acid diethylamide (LSD). It also provides an overview of legal aspects, and regulations surrounding psychedelics in the US & Europe, emphasizing their Schedule I classification due to potential misuse. The United States Food & Drug Administration (USFDA) closely monitors psychedelics, employing expedited pathways for evaluation. Further, recent guidance from the FDA on considerations for clinical Investigations supports the safe development of psychedelics for human welfare. European Medicines Agency (EMA) regulators focus on atypical psychedelics, addressing challenges in safety and efficacy. Marketed products, such as Spravato nasal spray, face limited distribution due to safety concerns. The call for careful regulation and legislation is essential for harnessing psychedelics' potential for therapeutic benefits and human welfare.
Fragile promise of psychedelics in psychiatry

Cédric Lemarchand,Raphaël Chopin,Morgane Paul,Alain Braillon,Lisa Cosgrove,Ioana Cristea,Eiko I Fried,Erick H Turner,Florian Naudet

DOI: https://doi.org/10.1136/bmj-2024-080391

2024-11-27

BMJ

Abstract:The US clinical market for ketamine, estimated at $3.1bn in 2022 and expected to expand at 10.6% a year until 2030,1 is just one of many signs of renewed interest in the use of psychedelics to treat psychiatric conditions.2 Various mind altering drugs have already entered the market, including esketamine nasal spray, which the US Food and Drug Administration approved in 2019. And in 2022 the Australian Therapeutic Goods Administration (TGA) allowed psilocybin and 3,4-methylenedioxymethamphetamine (MDMA) to be prescribed by authorised physicians for psychiatric conditions such as depression and post-traumatic stress disorder. The decision was taken despite an independent scientific report commissioned by the TGA advising against authorisation because the certainty of evidence for benefits was low or very low.3Psychedelics, the lay term for substances classified as hallucinogens, have various targets and distinct purported mechanisms of action. For instance, psilocybin is a serotoninergic agonist, whereas esketamine is a N-methyl-D-aspartate (NMDA)...

medicine, general & internal
Critical review of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder: Unanswered questions and future directions

Alex P. Hood,Chris E. Corlett,Cameron T. Alldredge,Gary R. Elkins

DOI: https://doi.org/10.1556/2054.2024.00383

2024-07-18

Journal of Psychedelic Studies

Abstract:Abstract Background and Aims Post-Traumatic Stress Disorder (PTSD) is a debilitating condition that affects a sizable proportion of U.S. civilians, military personnel, and veterans. 3,4-Methylenedioxymethamphetamine-Assisted Therapy (MDMA-AT) is a novel treatment approach for PTSD that has both stirred media enthusiasm and drawn criticism. This critical review analyzes individual randomized, controlled trials of MDMA-AT and provides a narrative synthesis. Methods A library search and analysis of extant literature reviews was conducted to identify publications containing original research findings with inter-group statistical comparisons from randomized, controlled trials of MDMA-AT. Seven articles were identified. One pilot study was excluded due to a lack of inter-group comparison. Results To date, six (four Phase II and two Phase III) randomized, controlled trials of MDMA-AT have been published which met criteria for inclusion in this review. Study design, sponsor, recruitment methods, and participant demographics are similar across trials. Conclusions Five out of six reviewed studies provide evidence for the apparent safety and efficacy of MDMA-AT. However, the lack of suitable comparison condition, poor blinding, and rigid study design across trials make interpretation of results difficult. In addition, the high costs of MDMA-AT and lack of head-to-head comparisons with validated PTSD therapies cast doubt on its potential promise as a treatment. The role of the sponsoring organization behind all trials may further introduce bias into findings. Though research to date is encouraging, there is not yet sufficient evidence to suggest that MDMA-AT should be see widespread adoption over current, validated forms PTSD of treatment.
The Need for Psychedelic-Assisted Therapy in the Black Community and the Burdens of Its Provision

Darron T Smith,Sonya C Faber,NiCole T Buchanan,Dale Foster,Lilith Green

DOI: https://doi.org/10.3389/fpsyt.2021.774736

2022-01-20

Abstract:Psychedelic medicine is an emerging field that examines entheogens, psychoactive substances that produce non-ordinary states of consciousness (NOSC). 3,4-methylenedioxymethamphetamine (MDMA) is currently in phase-3 FDA clinical trials in the United States (US) and Canada to treat the symptoms of posttraumatic stress disorder (PTSD). MDMA is used in conjunction with manualized therapy, because of its effectiveness in reducing fear-driven stimuli that contribute to trauma and anxiety symptoms. In 2017, the FDA designated MDMA as a "breakthrough therapy," signaling that it has advantages in safety, efficacy, and compliance over available medication for the treatment of trauma-, stress-, and anxiety-related disorders such as PTSD. In the US and Canada, historical and contemporary racial mistreatment is frequently experienced by Black people via a variety of macro and micro insults. Such experiences trigger physiological responses of anxiety and fear, which are associated with chronically elevated stress hormone levels (e.g., cortisol and epinephrine), similar to levels documented among those diagnosed with an anxiety disorder. This paper will explore the benefits of entheogens within psychedelic assisted-therapy and their potential benefits in addressing the sequelae of pervasive and frequent negative race-based experiences and promoting healing and thriving among Black, Indigenous and other People of Color (BIPOC). The author(s) discuss the ethical responsibility for providing psychedelic-assisted therapy within a culturally competent provider framework and the importance of psychedelic researchers to recruit and retain BIPOC populations in research and clinical training.
FDA Denies Approval of MDMA-Assisted Therapy for PTSD

Karen Roush

DOI: https://doi.org/10.1097/01.NAJ.0001081684.80872.ce

2024-11-01

Abstract:The agency cited potential dangers and flaws in research methodology.
Psychedelic Therapy: A Primer for Primary Care Clinicians—Lysergic Acid Diethylamide (LSD)

Bryce D. Beutler,Kenneth Shinozuka,Burton J. Tabaac,Alejandro Arenas,Kirsten Cherian,Viviana D. Evans,Chelsey Fasano,Owen S. Muir

DOI: https://doi.org/10.1097/mjt.0000000000001726

2024-03-23

American Journal of Therapeutics

Abstract:Lysergic acid diethylamide (LSD) is a hallucinogenic agent. In the mid-20 th century, it was used to augment psychoanalysis and to treat alcohol use disorder. However, LSD was banned in 1970 in part because of concerns that it could bring about or exacerbate mental illness. Its therapeutic potential remains incompletely understood.

pharmacology & pharmacy
How to Make Psychedelic-Assisted Therapy Safer

Daniel Villiger

DOI: https://doi.org/10.1017/s0963180124000604

2024-12-04

Cambridge Quarterly of Healthcare Ethics

Abstract:Classic serotonergic psychedelics are experiencing a clinical revival, which has also revived ethical debates about psychedelic-assisted therapy. A particular issue here is how to prepare and protect patients from the vulnerability that the psychedelic state creates. This article first examines how this vulnerability manifests itself, revealing that it results from an impairment of autonomy: psychedelics diminish decision-making capacity, reduce controllability, and limit resistance to external influences. It then analyzes the strengths and weaknesses of five safety measures proposed in the literature, what aspect of the patient's vulnerability they seek to reduce, and how they can be optimized. The analysis shows that while preparatory sessions, advance directives, and specific training and oversight are useful, starting with a lower dosage and no therapy is less so. Finally, the article presents a safety measure that has been overlooked in the literature but could be highly effective and feasible: bringing a close person to the psychedelic session.

social sciences, biomedical,health care sciences & services,health policy & services
MDMA therapy for PTSD rejected by FDA panel

Sara Reardon

DOI: https://doi.org/10.1038/d41586-024-01622-3

IF: 64.8

2024-06-05

Nature

Abstract:Scientific advisors vote overwhelmingly that the risks of MDMA treatment for post-traumatic stress disorder outweigh the benefits. Scientific advisors vote overwhelmingly that the risks of MDMA treatment for post-traumatic stress disorder outweigh the benefits.

multidisciplinary sciences
In the new era of psychedelic assisted therapy: A systematic review of study methodology in randomized controlled trials

Haass-Koffler, Carolina L.

DOI: https://doi.org/10.1007/s00213-024-06598-6

2024-04-30

Psychopharmacology

Abstract:Recent years have seen a resurgence in randomized, placebo controlled trials (RCTs) utilizing non-classical psychedelics (e.g. 3,4-methyl enedioxy methamphetamine [MDMA]), and classical psychedelics (e.g. psilocybin, lysergic acid diethylamide [LSD], and N,N-dimethyltryptamine [DMT/ayahuasca]) in conjunction with assisted therapy (AT) for psychiatric disorders. A notable methodological challenge in psychedelic AT, however, is the complexity of blinding procedures. The lack of efficacious blinding can introduce considerable response bias, reduce internal validity, and compromise participant retention. This systematic review examines design and blinding techniques in RCTs utilizing psychedelics and placebo for the treatment of psychiatric disorders. The aim of this work is to identify factors that may inform future RTC design for conducting psychedelics research. We conducted a systematic review of PubMed, MEDLINE, CINAHL, Cochrane Central Register of Controlled Trials (CENTRAL), Psycinfo, Embase, and Web of Science Core Collection to examine: (1) placebo selection, (2) study design, and (3) integrity of blinding measures. Sixteen publications were identified as meeting the criteria for a systematic review. Our findings suggest that traditional placebo administration is insufficient to control for expectancy confounds. Consequently, experimental methodology that limits personnel unblinding and the use of an active placebo are important considerations when designing prospective clinical studies involving psychedelics.

pharmacology & pharmacy,neurosciences,psychiatry

Psychedelic Therapy Scrutinized by FDA Advisory Committee?

Psychedelic research at a crossroads

Decision-Making around Psychedelics for Depression and Anxiety: a Model Based on Online Discussions

Psychedelics field looks ahead after FDA advisers' rejection

Psychedelic Therapy: A Primer for Primary Care Clinicians—3,4-Methylenedioxy-methamphetamine (MDMA)

Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines

A regulatory framework review of Schedule I psychedelics in the United States

The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns

Psychedelic Therapy: A Primer for Primary Care Clinicians—The Strengths, Weaknesses, Opportunities, and Threats of Psychedelic Therapeutics

Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money

Developing an Ethics and Policy Framework for Psychedelic Clinical Care

Psychedelics in Addiction Treatment—Navigating a Sociopolitical Rift

Exploring the regulatory framework of psychedelics in the US & Europe

Fragile promise of psychedelics in psychiatry

Critical review of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder: Unanswered questions and future directions

The Need for Psychedelic-Assisted Therapy in the Black Community and the Burdens of Its Provision

FDA Denies Approval of MDMA-Assisted Therapy for PTSD

Psychedelic Therapy: A Primer for Primary Care Clinicians—Lysergic Acid Diethylamide (LSD)

How to Make Psychedelic-Assisted Therapy Safer

MDMA therapy for PTSD rejected by FDA panel

In the new era of psychedelic assisted therapy: A systematic review of study methodology in randomized controlled trials